A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
← catalyst calendarNCT07543055 · readout in 1,266 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
36estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-10 | estimated | When the study began enrolling |
| Primary completion | 2030-02-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-04-25 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Prostate Cancer
Intervention
- Genetic: BPX-601
Primary outcomes
what the primary-completion date above is the date OFOccurrence of Treatment Emergent Adverse Events (TEAEs)
measured Up to 4 years
Occurrence of Dose Limiting Toxicities (DLTs)
measured Up to Day 28
Occurrence of Adverse Events of Special Interest (AESIs)
measured Up to 4 years
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed